Irene L. M. Reijers

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers et al. · Nature Medicine · 2021 · 322 citations

Biomarker Analyses, Medicine, Melanoma +8

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · Nature Medicine · 2022 · 322 citations · Full text

Surgical Oncology, Oncology, Prado Trial +10

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

Rebecca Simpson, Erin R. Shanahan, Marcel Batten et al. · Nature Medicine · 2022 · 216 citations

Dysbiosis, Host-microbe Interactions, Immunology +13

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers et al. · The Lancet Oncology · 2021 · 201 citations

Oncology, Anti-pd-1 Therapy, Melanoma +10

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

C. Owen, Xue Bai, Serigne Lo et al. · Annals of Oncology · 2021 · 172 citations · Full text

Tumor Immunology, Melanoma, Immunology +6